National Alzheimer's Plan requires collaboration, PhRMA says

04/25/2013 | Hill, The

Every part of the medical innovation ecosystem must work together if the federal government is serious about the successful implementation of its Alzheimer's plan, PhRMA President and CEO John J. Castellani writes. Strong partnerships and collective thinking among biopharmaceutical research companies, patient advocacy groups, federal research institutions and universities are needed to find efficient remedies to mitigate the financial and emotional burdens of Alzheimer's and other conditions, Castellani writes. Short-sighted policies that weaken progress and innovation should not endanger the country's strong research enterprise, he adds.

View Full Article in:

Hill, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC